For Immediate Release
Chicago, IL – November 17, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Arcellx, Inc. (
ACLX Quick Quote ACLX - Free Report) , Bristol Myers Squibb ( BMY Quick Quote BMY - Free Report) , Solid Biosciences Inc. ( SLDB Quick Quote SLDB - Free Report) , Vertex Pharmaceuticals Inc. ( VRTX Quick Quote VRTX - Free Report) and CRISPR Therapeutics ( CRSP Quick Quote CRSP - Free Report) . Here are highlights from Thursday’s Analyst Blog: Biotech Stock Roundup: Drug Approvals, Gene Therapy & More
With the conclusion of the third-quarter earnings for the biotech sector, the focus is back on regular drug approvals and other pipeline and regulatory updates. Quite a few companies came out with important updates on their key candidates
Recap of the Week’s Most Important Stories: : Shares of Arcellx Surges on Deal Expansion Arcellx, Inc. gained after the company and partner Kite, a Gilead company, announced an expansion of their existing agreement. The companies collaborated in December 2022 to co-develop and co-commercialize Arcellx's CART-ddBCMA candidate for the treatment of patients with relapsed or refractory multiple myeloma.
Kite has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma. The companies also expanded the scope of the collaboration for Arcellx's CART-ddBCMA to include lymphomas.
Per the terms of the agreement, Arcellx will receive an upfront cash payment of $85 million at closing and an equity investment of $200 million. It will also be eligible for potential milestone payments, including the advancement of lymphoma and the license for ARC-SparX, as well as additional milestones, to offset prespecified development costs over a limited period of time.
This infusion of cash is expected to extend Arcellx’s cash runway into 2027. Gilead will have an approximate 13% stake following this investment.
: Bristol Myers’ Drug Approval Bristol Myers Squibb announced that the FDA approved pipeline candidate repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Repotrectinib is a tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions.
The candidate has been approved under the brand name Augtyro as an oral therapy. The approval is based on positive results from the TRIDENT-1 study that evaluated Augtyro in TKI-naïve and TKI-pretreated patients. Results showed Augtyro successfully achieved a high objective response rate and durable response.
The candidate was added to BMY’s portfolio with the acquisition of Turning Point Therapeutics in August 2022. The approval will add Augtyro to Bristol Myers’ growing and differentiated NSCLC portfolio, expanding the company’s presence in precision medicine.
: Solid Biosciences Up on IND Clearance Solid Biosciences Inc. announced that it has obtained FDA clearance for an investigational new drug (IND) application for SGT-003, the company’s next-generation Duchenne Muscular Dystrophy (Duchenne) gene therapy candidate.
Consequently, SLDB plans to initiate a phase I/II study, SGT-003-101, to determine the safety and tolerability of SGT-003 in pediatric patients with DMD at a dose of 1E14vg/kg. The study is a first-in-human, open-label, multicenter study. Solid Biosciences shares surged on the same.
SGT-003 will be administered as a one-time intravenous infusion to patients in two cohorts with a minimum of three patients each, with the potential for cohort expansion. Cohort 1 will study patients aged between four and six years of age with DMD. Long-term safety and efficacy will be evaluated for a total of five years following treatment.
: Update From VRTX, CRSP Vertex Pharmaceuticals Inc. and partner CRISPR Therapeutics announced that the U.K. Medicines and Healthcare products Regulatory Agency (“MHRA”) has granted conditional marketing authorization to their CRISPR/Cas9 gene-edited therapy, exagamglogene autotemcel (exa-cel), for the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
The therapy has been approved under the brand name Casgevy for the treatment of eligible patients 12 years of age and older with SCD with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen-matched related hematopoietic stem cell donor is not available.
The two global trials of Casgevy in SCD and TDT met their respective primary outcome of becoming free from severe VOCs or transfusion-independent for at least 12 consecutive months. These benefits are potentially expected to be life-long once achieved. Exa-cel was granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA.
The Nasdaq Biotechnology Index has lost 0.90% in the past five trading sessions. Among the biotech giants, Vertex has lost 7.33% during the period. Over the past six months, shares of Moderna have plunged 41.39%. (See the last biotech stock roundup here:
). Biotech Stock Roundup: BMYs Q3 Results, PTCT Up on Deal, BEAMs Restructuring News Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of
+46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.